Literature DB >> 20717706

Do nutraceutics play a role in the prevention and treatment of colorectal cancer?

Brian Markle1, Elizabeth J May, Adhip P N Majumdar.   

Abstract

Colorectal cancer is the third most common cancer worldwide with a 5-year survival of 50%. Current chemotherapeutic regimens used for advanced colorectal cancer provide an average survival of approximately 20 months. Non-toxic agents such as nutraceutics and supplements have been shown to aid in the prevention and adjuvant treatment of colorectal cancer. This article will discuss the epidemiology, progression, prevention, treatment, and recurrence of colorectal cancer and the role of nutraceutics and supplements in the treatment process.

Entities:  

Mesh:

Year:  2010        PMID: 20717706     DOI: 10.1007/s10555-010-9234-3

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  13 in total

1.  Regulation of colon cancer recurrence and development of therapeutic strategies.

Authors:  Shailender Singh Kanwar; Anuradha Poolla; Adhip Pn Majumdar
Journal:  World J Gastrointest Pathophysiol       Date:  2012-02-15

2.  Role of curcumin in preventing familial adenomatous polyposis.

Authors:  Adhip P N Majumdar
Journal:  Dig Med Res       Date:  2018-09-11

3.  Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer.

Authors:  Maresa McGettigan; Chris R Cardwell; Marie M Cantwell; Mark A Tully
Journal:  Cochrane Database Syst Rev       Date:  2020-05-03

4.  Proteins in Soy Might Have a Higher Role in Cancer Prevention than Previously Expected: Soybean Protein Fractions Are More Effective MMP-9 Inhibitors Than Non-Protein Fractions, Even in Cooked Seeds.

Authors:  Ana Lima; Jennifer Oliveira; Filipe Saúde; Joana Mota; Ricardo Boavida Ferreira
Journal:  Nutrients       Date:  2017-02-27       Impact factor: 5.717

5.  Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology.

Authors:  Mohammad Rostami-Nejad; Sina Rezaei Tavirani; Vahid Mansouri; Somayeh Jahani-Sherafat; Hamideh Moravvej Farshi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

6.  A signature of hypoxia-related factors reveals functional dysregulation and robustly predicts clinical outcomes in stage I/II colorectal cancer patients.

Authors:  Yi-Feng Zou; Yu-Ming Rong; Ying-Xin Tan; Jian Xiao; Zhao-Liang Yu; Yu-Feng Chen; Jia Ke; Cheng-Hang Li; Xi Chen; Xiao-Jian Wu; Ping Lan; Xu-Tao Lin; Feng Gao
Journal:  Cancer Cell Int       Date:  2019-09-23       Impact factor: 5.722

7.  Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse.

Authors:  Rabeah A Al-Temaimi; Tuan Zea Tan; Makia J Marafie; Jean Paul Thiery; Philip Quirke; Fahd Al-Mulla
Journal:  Int J Mol Sci       Date:  2016-04-28       Impact factor: 5.923

8.  Identification of potential long non-coding RNA biomarkers associated with the progression of colon cancer.

Authors:  Jingwen Li; Weinan Xue; Junli Lv; Peng Han; Yanlong Liu; Binbin Cui
Journal:  Oncotarget       Date:  2017-05-17

9.  A long non-coding RNA signature for predicting survival in patients with colorectal cancer.

Authors:  Yi-Lin Wang; Jun Shao; Xiaohong Wu; Tong Li; Ming Xu; Debing Shi
Journal:  Oncotarget       Date:  2017-12-19

10.  The effect of MTHFD2 on the proliferation and migration of colorectal cancer cell lines.

Authors:  Yameng Wei; Pengfei Liu; Qian Li; Juan Du; Yani Chen; Yu Wang; Haiyan Shi; Yanfeng Wang; Huahua Zhang; Wanjuan Xue; Yi Gao; Dan Li; Yun Feng; Jing Yan; Jiming Han; Jing Zhang
Journal:  Onco Targets Ther       Date:  2019-08-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.